Market's view on Oxford Biodyn
Published on April 2024
- Stock watchers discuss a stock that seems to be below placing price, yet uptake numbers are still needed.
- There are concerns about a director selling shares or potentially being diluted in a fundraise, which is seen as a potentially negative sign without additional information.
- Stock watchers mention the overall disappointing nature of the AIM market, referring to it as a platform where companies frequently carry out placings without necessarily creating shareholder value.
- The affordability and efficiency of the Stockholm 3 test are compared with the PSE test for prostate cancer, with both showing benefits but the PSE test providing a significantly higher reduction in the need for biopsies.
- There’s discussion about the financial benefits for insurers in the US to support the PSE test, as it potentially saves costs on unnecessary biopsies and the treatment of complications arising from biopsies.
- Stock watchers express optimism about the potential for the company’s prostate test, especially given the high costs and risks associated with biopsies.
- Concerns are raised about the company’s need for additional fundraising within a year due to potential ongoing losses and lack of significant revenue increase.
- The company’s progress is noted, with incremental sales of the PSE tests, but there’s a long way to go to reach targets.
- There’s an ongoing discussion about the recent fundraising efforts, with stock watchers considering it a positive move for addressing funding concerns and potentially stabilising the share price.